Your monthly Iluvien cost savings if eligible
If you are eligible for the Iluvien patient assistance program you can receive your medication for free. Our monthly service fee of $49 per medication covers the cost of our services in applying for the program and requesting your ongoing refills on your behalf. If you obtain your Iluvien through NiceRx, you will only pay $49 a month regardless of the retail price of your medication.
Am I eligible for the Iluvien patient assistance program?
You could receive your Iluvien without paying the full retail price if you meet the eligibility criteria for assistance. The eligibility requirements are set by the pharmaceutical companies that are providing assistance programs. At NiceRx, we review each application individually, although the main factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for Iluvien patient assistance?
We do everything that we can to take the hassle and stress out of applying for patient assistance programs. Simply start by filling in our enrollment application. We will ask for details about your healthcare provider, your insurance, and your household income. This information is required by the pharmaceutical companies you are applying to for assistance. We may also be able to help you access patient assistance for other medications that you have been prescribed, so be sure to tell us about any medications you are taking as well as Iluvien.
NiceRx will review the information you have provided, and if we determine that you may be eligible for assistance, we will seek to enroll you in the Iluvien patient assistance program. We will handle the enrollment process for you by working with your healthcare provider and preparing all the required paperwork for your doctor to sign. We will also request your Iluvien medication refills on your behalf for up to 1 year once you are enrolled in the program.
Is NiceRx an Iluvien coupons provider?
At NiceRx, we help eligible individuals access the Iluvien patient assistance program. This means that we are not an Iluvien coupon, an Iluvien discount card, or an Iluvien copay card provider. We do not offer any medication trial offers or free Iluvien samples.
Can NiceRx help me get Iluvien if I have insurance?
We may be able to help you if you have insurance, including if your insurance company will not pay for your Iluvien medication, or you have a high copay or coinsurance responsibility. We may even be able to assist if you do not have insurance. Please fill in our enrollment application to find out more.
How much does Iluvien cost without insurance?
Iluvien costs without insurance will vary depending on how many you buy and the retailer you buy it from. As a guide, Iluvien intravitreal implant 0.19 mg will typically cost around $9,200 for 1 implant. If you obtain your medication through NiceRx, you will pay a flat monthly rate of $49 per medication regardless of its retail price.
How much does Iluvien cost with insurance?
The copay of Iluvien will vary in line with the specific terms of your healthcare plan. For further details about what you may need to pay, your insurance provider or pharmacist will be able to calculate the copay costs with your current insurance.
What is Iluvien?
Iluvien is an FDA (U.S. Food and Drug Administration) approved medication manufactured for Alimera Sciences, Inc. Iluvien contains a corticosteroid (steroid) and is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (30 mm Hg). Iluvien is an injectable intravitreal micro implant providing sustained-release, low-dose fluocinolone acetonide.
Diabetic macular edema (DME) is a common complication of diabetic retinopathy and may lead to severe visual loss. DME is a condition characterized by the breakdown of the blood-retina barrier causing an increase in vascular permeability. Patients who have failed anti-VEGF therapy but did well with shorter-acting intravitreal corticosteroid injections like triamcinolone acetonide or dexamethasone are the best candidates for Iluvien.
Laser photocoagulation has been the standard of care for DME for many years. More recently, intravitreal injections of anti-VEGF agents such as ranibizumab and bevacizumab have become more common, as well as corticosteroids. Ranibizumab is an anti-VEGF antibody that is effective in reducing central macular thickness (CMT) and improving best-corrected visual acuity (BCVA) in DME over a 12- to 36-month follow-up period.
The efficacy and safety of Iluvien have been examined in controlled trials, called the FAME studies. A total of 956 patients were randomized 2:2:1 to receive 0.2 μg/day fluocinolone acetonide, 0.5 μg/day fluocinolone acetonide, or sham injection. The endpoint was the percentage of patients with improvement from baseline in BCVA of 15 letters or more. Follow-up continued after the 2-year primary endpoint, and the 3-year results have been published.
At month 36, the percentage of patients showing an improvement of 15 letters or more was 28.7% in the low-dose group and 27.8% in the high-dose group, and 18.9% in the sham group. At month 36, almost all phakic patients in the fluocinolone acetonide implant groups developed cataracts, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group, 8.1% in the high-dose group, and 0.5% in the sham group.
The median duration of DME at baseline was 3 years. Therefore, based on a preplanned subgroup analysis, outcomes were assessed in patients having DME for less than 3 years and for 3 years or more at baseline. Based on the evidence reported in the FAME studies, particularly in patients with chronic DME, Iluvien has been approved in the European Union for the treatment of visual impairment due to chronic macular edema considered insufficiently responsive to available therapies.
What doses of Iluvien are available?
Iluvien is available as a non-bioerodable intravitreal implant, in the following doses: 0.19 mg fluocinolone acetonide in a drug delivery system.
The intravitreal injection procedure should be carried out by a healthcare provider who will place the Iluvien implant in your eye under aseptic conditions. Patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Iluvien is preloaded into a single-use applicator for injection of the implant directly into the vitreous.
Your doctor may prescribe other medications to help control the pressure inside your eyes. Increased pressure inside the eye (ocular hypertension) can damage the optic nerve and lead to permanent blindness. You may need to continue using these other medications for several weeks.
Iluvien active ingredients
Iluvien contains fluocinolone acetonide as the active ingredient.
Iluvien side effects
The most common adverse events of Iluvien in clinical trials include:
- Cataract development requiring cataract surgery
- Increases in intraocular pressure (IOP)
In rare instances, Iluvien can cause more serious side effects. These can include:
- Visual acuity and field defects
- Eye inflammation
- Increased intraocular pressure
- Retinal detachments
- Secondary ocular infections due to bacteria, fungi, or viruses
- The implant may migrate into the anterior chamber if the posterior lens capsule is not intact
- Carcinogenesis, mutagenesis
- Impairment Of Fertility
Your doctor will assess the benefits of using Iluvien against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Iluvien to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Iluvien drug interactions
There is currently no data for Iluvien interactions with other medications. Tell your healthcare provider about all the medicines you take, including prescription drugs and over-the-counter medicines, vitamins, and herbal supplements.
You should not use Iluvien if you:
- Are allergic to the active ingredient fluocinolone acetonide (FAC)
- Are allergic to any of the other ingredients in Iluvien
- Have ocular or periocular infections
- Have glaucoma
Talk to your doctor before using Iluvien if you:
- Are taking any of the medications that could interact with Iluvien
- Are pregnant or are planning to become pregnant
- Are breastfeeding or are planning to breastfeed
Iluvien is the trademark brand name for the fluocinolone acetonide implant, manufactured for Alimera Sciences, Inc. A generic version of fluocinolone acetonide is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Iluvien savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.